文献速递乳腺癌胸部肿瘤头颈与中枢神经肿瘤

基于基因组的放疗剂量调整模型(GARD):一项回顾性队列研究

A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
PubMed 文献 · Lancet Oncol · 2016-12-18

研究利用基因表达放疗敏感性指数与线性二次模型推导基因组调整放疗剂量(GARD),在TCC队列8271份样本中计算GARD,并在5个临床队列中评估其与临床结局的独立关联。结果显示GARD在相同放疗剂量下仍分布广泛,且可独立预测乳腺癌、肺癌、胶质母细胞瘤和胰腺癌的临床结局。

要点

  • GARD模型可基于肿瘤分子特征个体化调整放疗剂量。
  • 相同病种统一剂量下GARD值仍分布广泛(范围1·66-172·4)。
  • GARD可独立预测乳腺癌、肺癌、胶质母细胞瘤和胰腺癌结局。

核心结论

  • 基于GARD的临床模型可能实现按肿瘤放射敏感性个体化调整放疗剂量,并可为设计基因组指导的放射肿瘤学临床试验提供框架。

研究设计与样本

  • 回顾性、基于队列的研究,使用前瞻性观察性Total Cancer Care(TCC)方案数据计算原发肿瘤的GARD。
  • 采用多变量Cox模型在五个临床队列中评估GARD与临床结局的独立关联:Erasmus乳腺癌队列(n=263)、Karolinska乳腺癌队列(n=77)、Moffitt肺癌队列(n=60)、Moffitt胰腺癌队列(n=40)、癌症基因组图谱胶质母细胞瘤患者队列(n=98)。

主要发现

  • 在TCC队列8271份组织样本中计算GARD,尽管各病种内放疗剂量统一,GARD值范围仍广泛(范围1·66-172·4)。
  • 中位GARD值在胶质瘤和肉瘤中最低,在宫颈癌和口咽头颈癌中最高,且肿瘤类型组内GARD值分布广泛。
  • GARD可独立预测乳腺癌、肺癌、胶质母细胞瘤和胰腺癌的临床结局。
  • 在Erasmus乳腺癌队列中,高GARD值患者5年无远处转移生存长于低GARD值患者(风险比2·11,95%CI 1·13-3·94,p=0·018)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite its common use in cancer treatment, radiotherapy has not yet entered the era of precision medicine, and there have been no approaches to adjust dose based on biological differences between or within tumours. We aimed to assess whether a patient-specific molecular signature of radiation sensitivity could be used to identify the optimum radiotherapy dose. METHODS: We used the gene-expression-based radiation-sensitivity index and the linear quadratic model to derive the genomic-adjusted radiation dose (GARD). A high GARD value predicts for high therapeutic effect for radiotherapy; which we postulate would relate to clinical outcome. Using data from the prospective, observational Total Cancer Care (TCC) protocol, we calculated GARD for primary tumours from 20 disease sites treated using standard radiotherapy doses for each disease type. We also used multivariable Cox modelling to assess whether GARD was independently associated with clinical outcome in five clinical cohorts: Erasmus Breast Cancer Cohort (n=263); Karolinska Breast Cancer Cohort (n=77); Moffitt Lung Cancer Cohort (n=60); Moffitt Pancreas Cancer Cohort (n=40); and The Cancer Genome Atlas Glioblastoma Patient Cohort (n=98). FINDINGS: We calculated GARD for 8271 tissue samples from the TCC cohort. There was a wide range of GARD values (range 1·66-172·4) across the TCC cohort despite assignment of uniform radiotherapy doses within disease types. Median GARD values were lowest for gliomas and sarcomas and highest for cervical cancer and oropharyngeal head and neck cancer. There was a wide range of GARD values within tumour type groups. GARD independently predicted clinical outcome in breast cancer, lung cancer, glioblastoma, and pancreatic cancer. In the Erasmus Breast Cancer Cohort, 5-year distant-metastasis-free survival was longer in patients with high GARD values than in those with low GARD values (hazard ratio 2·11, 95% 1·13-3·94, p=0·018). INTERPRETATION: A GARD-based clinical model could allow the individualisation of radiotherapy dose to tumour radiosensitivity and could provide a framework to design genomically-guided clinical trials in radiation oncology. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Scott JG, Berglund A, Schell MJ, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2016. PMID: 27993569. doi:10.1016/S1470-2045(16)30648-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。